Published Work

PubMed link for Dr. Prosperi

Prosperi, J.R., Mallery, S.R, Kigerl, K.A., Erfurt, A.A., and Robertson, F.M. (2004) Invasive and Angiogenic Phenotype of MCF-7 Human Breast Tumor Cells Expressing Human Cyclooxygenase-2. Prostaglandins Other Lipid Mediat, Apr;73(3-4):249-64.

Prosperi, J.R., and Robertson, F.M. (2006) Cyclooxygenase-2 Directly Regulates Gene Expression of P450 Cyp19 Aromatase Promoter Regions pII, pI.3, and pI.7, and Estradiol Production in Human Breast Tumor Cells. Prostaglandins Other Lipid Mediat, Oct;81(1-2):55-70.

Robertson, F.M., Ming-Cheng Cheng, M., Prosperi, J.R., Gaspari, M., Terracciano, R., Green-Church, K.B., Vandre, D.D., Cuda, G., and Ferrari, M. (2006) Nanochips for mining the serum and tumor proteome: novel nanochips for sensitive and reproducible identification of the low molecular weight proteome in serum isolated from mice bearing highly invasive human breast tumor xenografts. Nanomedicine. Dec;2(4):295.

Robertson, F.M., Mallery, S.R., Bergdall-Costell, V.K., Cheng, M, Pei, P, Prosperi, J.R., Ferrari, M. (2007) Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. Mar-Apr; 27(2): 719-27.

Nijdam, A.J., Zianni, M.R., Herderick, E.E., Cheng, M.M., Prosperi, J.R., Robertson, F.A., Petricoin, E.F., Liotta, L.A., Ferrari, M. (2009) Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. J Proteome Res. 2009 Mar;8(3):1247-54

Prosperi, J.R., Becher, K.R., Willson, T.A., Collins, M.H., Witte, D.P., and Goss, K.H. (2009) The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland. J. Cell Phys, Aug;220(2):319-31. *These authors contributed equally to this work.

Prosperi, J.R., and Goss, K.H. (2010) A Wnt-ow of Opportunity: Targeting the Wnt/b-catenin Pathway in Breast Cancer. Curr Drug Targets, Sep;11(9):1074-88.

Prosperi, J.R., Lue, H.H., and Goss. K.H. (2011) Dysregulation of the Wnt Pathway in Solid Tumors. In: Targeting the Wnt Pathway in Cancer. Eds: Kathleen Goss and Michael Kahn, Springer, New York, pp. 81-128.

Prosperi, J.R. and Goss, K.H. (2011) Wnt Pathway-independent Activities of the APC Tumor Suppressor. In: Tumor Suppressors, Ed: Susan D. Nguyen, Nova Science Publishers, pp. 105-132.

Prosperi, J.R., Khramtsova, G.F., Khramtosov, A.I., and Goss, K.H. (2011) Loss of APC promotes PyMT-mediated mammary tumorigenesis. PLoS ONE, 6(12):e29339.

Prosperi, J.R., and Goss, K.H. (2012) Wnt signaling in lactation. In: Lactation: Natural Processes, Physiological Responses and Role in Maternity, Nova Science Publishers. Eds: Lisa M. Reyes Cruz and Douglas C. Ortiz Gutierrez.

Odenwald, M.A., Prosperi, J.R., and Goss, K.H. (2013) Localization of the APC tumor suppressor at cell protrusions is required for breast cancer cell migration and invasion. BMC Cancer, 13:12. PMCID: PMC3556124 *These authors contributed equally to this work.

Lesko, A.C., Goss, K.H., and Prosperi, J.R. (2014) Exploiting APC Function as a Novel Cancer Therapy. Curr Drug Targets, Jan;15(1):90-102.

Prosperi, J.R. and Goss, K.H. (2014) Editorial: Targeting loss of tumor suppressors for cancer therapeutics. Curr Drug Targets, Jan;15(1):1.

Xu, J., Prosperi, J.R., Choudhury, N., Olopade, O., Goss, K.H. (2015) β-catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE, 10(2):20117097. PMCID: PMC4319896.

Lesko, A.C., Goss, K.H., Yang, F.F., Schwertner, A., Hulur, I., Onel, K., and Prosperi, J.R. (2015) The APC tumor suppressor is required for epithelial cell polarization and three-dimensional morphogenesis. BBA – Mol Cell Res, Mar; 1854(3):711-23. PMCID: PMC4327896.

VanKlompenberg, M.K., Bedalov, C., Fernandez Soto, K., and Prosperi, J.R. (2015) APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer, Jun 7;15:457. PMCID: PMC4458029.

Sawe, R.T., Kerper, M., Badve, S., Li, J., Sandoval-Cooper, M., Xie, J., Shi, Z., Patel, K., Chumba, D., Ofulla, A., Prosperi, J.R., Taylor, K., Stack, M.S., Mining, S., and Littlepage, L.E. (2016) Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer, Mar 10;16(1):204. PMID: 26964534.

Lesko, A.L. and Prosperi, J.R. (2016) Epithelial Membrane Protein 2 and b1 integrin signaling regulate APC-mediated processes. Exp Cell Res, Nov 24, Epub ahead of print. PMID: 27890644.

Torrorey, R., Mining, S.K., Ofulla, A.V., Patel, K.T., Guyah, B., Chumba, D., Prosperi, J.R., Kerper, M., Shi, Z., Sandoval-Cooper, M.J., Taylor, K., Badve, S., Stack, M.S., and Littlepage, L.E. (2017) Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya, Tropical Medicine and Health, Aug 4;45:19. PMID: 28794686

VanKlompenberg, M.K., Leyden, E., Arnason, A.H., Zhang, J-T, Stefanski, C.D., and Prosperi, J.R. (2017) APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. Oncotarget, in press.

Lyons, A.T., and Prosperi, J.R. (2017) Targeted Therapies in Breast Cancer. In: Resistance to Targeted Therapies in Breast Cancer. Ed: Jenifer R. Prosperi, Springer, New York, pp. 139-154.

Stefanski, C.D., and Prosperi, J.R. (2019) Role of Wnt/β-catenin Pathway in Cancer Signaling. In Badve S. and Kumar H. (eds) Predictive Biomarkers in Oncology. Springer, Cham. ISBN: 973-3-319-95227-7.

Cole, J.M., Simmons, K., and Prosperi, J.R. (2019) Effect of Adenomatous Polyposis Coli loss on tumorigenic potential in pancreatic ductal adenocarcinoma. Cells, Sep 14;8(9). PMID: 31540078. DOI: 10.3390/cells8091084

Stefanski, C.D., Keffler, K., McClintock, S., Milac, L., and Prosperi, J.R. (2019) APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia, Nov 20;21 (12): 1143-1150. PMID: 31759252. DOI: 10.1016/j.neo.2019.09.002

Stefanski, C.D., and Prosperi, J.R. (2020) Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response. Int J Mol Sci. 2020 Oct 22;21(21):E7844. doi: 10.3390/ijms21217844. PMID: 33105836.

Maloney, S.M.; Hoover, C.A.; Morejon-Lasso, L.V.; Prosperi, J.R. (2020) Mechanisms of Taxane Resistance. Cancers (Basel). 2020 Nov 10;12(11):E3323. doi: 10.3390/cancers12113323. PMID: 33182737.

Astarita, E.M., Maloney, S.M., Hoover, C.A., Berkeley, B., VanKlompenberg, M.K., Nair, T.M., and Prosperi, J.R. (2021) Adenomatous Polyposis Coli Loss Controls Cell Cycle Regulators and Response to Paclitaxel. In review at PLoS ONE

Publications: Publications

Published Work

Prosperi, J.R., Mallery, S.R, Kigerl, K.A., Erfurt, A.A., and Robertson, F.M. (2004) Invasive and Angiogenic Phenotype of MCF-7 Human Breast Tumor Cells Expressing Human Cyclooxygenase-2. Prostaglandins Other Lipid Mediat, Apr;73(3-4):249-64.

Prosperi, J.R., and Robertson, F.M. (2006) Cyclooxygenase-2 Directly Regulates Gene Expression of P450 Cyp19 Aromatase Promoter Regions pII, pI.3, and pI.7, and Estradiol Production in Human Breast Tumor Cells. Prostaglandins Other Lipid Mediat, Oct;81(1-2):55-70.

Nijdam, A.J., Zianni, M.R., Herderick, E.E., Cheng, M.M., Prosperi, J.R., Robertson, F.A., Petricoin, E.F., Liotta, L.A., Ferrari, M. (2009) Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. J Proteome Res. 2009 Mar;8(3):1247-54

Prosperi, J.R.*, Becher, K.R.*, Willson, T.A., Collins, M.H., Witte, D.P., and Goss, K.H. (2009) The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland. J. Cell Phys, Aug;220(2):319-31. *These authors contributed equally to this work.

Prosperi, J.R., and Goss, K.H. (2010) A Wnt-ow of Opportunity: Targeting the Wnt/b-catenin Pathway in Breast Cancer. Curr Drug Targets, Sep;11(9):1074-88.

Prosperi, J.R., Lue, H.H., and Goss. K.H. (2011) Dysregulation of the Wnt Pathway in Solid Tumors. In: Targeting the Wnt Pathway in Cancer. Eds: Kathleen Goss and Michael Kahn, Springer, New York, pp. 81-128.

Prosperi, J.R. and Goss, K.H. (2011) Wnt Pathway-independent Activities of the APC Tumor Suppressor. In: Tumor Suppressors, Ed: Susan D. Nguyen, Nova Science Publishers, pp. 105-132.

Prosperi, J.R., Khramtsova, G.F., Khramtosov, A.I., and Goss, K.H. (2011) Loss of APC promotes PyMT-mediated mammary tumorigenesis. PLoS ONE, 6(12):e29339.

Prosperi, J.R., and Goss, K.H. (2012) Wnt signaling in lactation. In: Lactation: Natural Processes, Physiological Responses and Role in Maternity, Nova Science Publishers. Eds: Lisa M. Reyes Cruz and Douglas C. Ortiz Gutierrez.

Odenwald, M.A.*, Prosperi, J.R.*, and Goss, K.H. (2013) Localization of the APC tumor suppressor at cell protrusions is required for breast cancer cell migration and invasion. BMC Cancer, 13:12. PMCID: PMC3556124 *These authors contributed equally to this work.

Lesko, A.C., Goss, K.H., and Prosperi, J.R. (2014) Exploiting APC Function as a Novel Cancer Therapy. Curr Drug Targets, Jan;15(1):90-102.

Prosperi, J.R. and Goss, K.H. (2014) Editorial: Targeting loss of tumor suppressors for cancer therapeutics. Curr Drug Targets, Jan;15(1):1.

Xu, J., Prosperi, J.R., Choudhury, N., Olopade, O., Goss, K.H. (2015) β-catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE, 10(2):20117097. PMCID: PMC4319896.

Lesko, A.C., Goss, K.H., Yang, F.F., Schwertner, A., Hulur, I., Onel, K., and Prosperi, J.R. (2015) The APC tumor suppressor is required for epithelial cell polarization and three-dimensional morphogenesis. BBA – Mol Cell Res, Mar; 1854(3):711-23. PMCID: PMC4327896.

VanKlompenberg, M.K., Bedalov, C., Fernandez Soto, K., and Prosperi, J.R. (2015) APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer, Jun 7;15:457. PMCID: PMC4458029.

Lesko, A.L. and Prosperi, J.R. (2016) Epithelial Membrane Protein 2 and b1 integrin signaling regulate APC-mediated processes. Exp Cell Res, Nov 24, Epub ahead of print. PMID: 27890644.

VanKlompenberg, M.K., Leyden, E., Arnason, A.H., Zhang, J-T, Stefanski, C.D., and Prosperi, J.R. (2017) APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. Oncotarget, in press.

​

Lyons, A.T., and Prosperi, J.R. (2017) Targeted Therapies in Breast Cancer. In: Resistance to Targeted Therapies in Breast Cancer. Ed: Jenifer R. Prosperi, Springer, New York, pp. 139-154.

Stefanski, C.D., and Prosperi, J.R. (2019) Role of Wnt/β-catenin Pathway in Cancer Signaling. In Badve S. and Kumar H. (eds) Predictive Biomarkers in Oncology. Springer, Cham. ISBN: 973-3-319-95227-7.

Cole, J.M., Simmons, K., and Prosperi, J.R. (2019) Effect of Adenomatous Polyposis Coli loss on tumorigenic potential in pancreatic ductal adenocarcinoma. Cells, Sep 14;8(9). PMID: 31540078. DOI: 10.3390/cells8091084

Stefanski, C.D., Keffler, K., McClintock, S., Milac, L., and Prosperi, J.R. (2019) APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia, Nov 20;21 (12): 1143-1150. PMID: 31759252. DOI: 10.1016/j.neo.2019.09.002

Stefanski, C.D., and Prosperi, J.R. (2020) Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response. Int J Mol Sci. 2020 Oct 22;21(21):E7844. doi: 10.3390/ijms21217844. PMID: 33105836.

Maloney, S.M.; Hoover, C.A.; Morejon-Lasso, L.V.; Prosperi, J.R. (2020) Mechanisms of Taxane Resistance. Cancers (Basel). 2020 Nov 10;12(11):E3323. doi: 10.3390/cancers12113323. PMID: 33182737.

Astarita, E.M., Maloney, S.M., Hoover, C.A., Berkeley, B., VanKlompenberg, M.K., Nair, T.M., and Prosperi, J.R. (2021) Adenomatous Polyposis Coli Loss Controls Cell Cycle Regulators and Response to Paclitaxel. In review at PLoS ONE

Prosperi, J.R., Becher, K.R., Willson, T.A., Collins, M.H., Witte, D.P., and Goss, K.H. (2009) The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland. J. Cell Phys, Aug;220(2):319-31. *These authors contributed equally to this work.

Odenwald, M.A., Prosperi, J.R., and Goss, K.H. (2013) Localization of the APC tumor suppressor at cell protrusions is required for breast cancer cell migration and invasion. BMC Cancer, 13:12. PMCID: PMC3556124 *These authors contributed equally to this work.